All Outputs (8)

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2025)
Journal Article
Horby, P. W., Staplin, N., Peto, L., Emberson, J. R., Campbell, M., Pessoa-Amorim, G., Basnyat, B., Thwaites, L., van Doorn, R., Hamers, R. L., Nel, J., Amuasi, J., Stewart, R., Ghosh, D., Blencowe, N., Desai, P., Easom, N., Majumdar, J., Hine, P., Chadwick, D., …Wittes, J. (2025). Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Infectious Diseases, https://doi.org/10.1016/S1473-3099%2825%2900093-3

Background
Molnupiravir and nirmatrelvir–ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia,... Read More about Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Lessons from the PROTECT-CH COVID-19 platform trial in care homes (2025)
Journal Article
Bath, P. M., Ball, J., Boyd, M., Gage, H., Glover, M., Godfrey, M., Guthrie, B., Hewitt, J., Howard, R., Jaki, T., Juszczak, E., Lasserson, D., Leighton, P., Leyland, V., Shen Lim, W., Logan, P., Meakin, G., Montgomery, A., Ogollah, R., Passmore, P., …Gordon, A. L. (2025). Lessons from the PROTECT-CH COVID-19 platform trial in care homes. Health Technology Assessment, https://doi.org/10.3310/MTRS8833

Background
Coronavirus disease-2019 was associated with significant mortality and morbidity in care homes in 2020–1. Repurposed antiviral drugs might reduce morbidity and mortality through reducing viral transmission, infection, replication and infl... Read More about Lessons from the PROTECT-CH COVID-19 platform trial in care homes.

Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease (2025)
Journal Article
Noor, N. M., Radford, S. J., Choodari-Oskooei, B., Gordon, M., Hart, A. L., Hepburn, T., Juszczak, E., Lindsay, J. O., Kennedy, N. A., Parmar, M. K. B., Jairath, V., & Moran, G. W. (2025). Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease. Nature Reviews Gastroenterology and Hepatology, 22, 364-366. https://doi.org/10.1038/s41575-025-01052-0

There is emerging interest in adaptive platform trials for inflammatory bowel disease. In this Comment, we present the results of a workshop that was convened to consider the opportunities and challenges of developing a platform trial in Crohn’s dise... Read More about Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease.

Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study (2025)
Journal Article
Hall, S. S., Juszczak, E., Birchenall, M., Elbourne, D., Beller, E., Chan, A.-W., Little, P., Montgomery, A. A., & Kahan, B. C. (2025). Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. BMJ Open, 15(2), Article e082917. https://doi.org/10.1136/bmjopen-2023-082917

Background Extensions to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and Consolidated Standards of Reporting Trials (CONSORT) reporting recommendations specifically for factorial trials have been developed by the Repor... Read More about Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study.

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2025)
Journal Article
Horby, P. W., Emberson, J. R., Thwaites, L., Campbell, M., Peto, L., Pessoa-Amorim, G., Staplin, N., Hamers, R. L., Amuasi, J., Nel, J., Kestelyn, E., Thanh Phong, N., Shrestha, A., Nasronudin, N., Sarkar, R., Ngoc Thach, P., Paudel, D., Sumardi, U., Stewart, R., Nelwan, E., …Landray, M. J. (2025). Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81, Article 103080. https://doi.org/10.1016/j.eclinm.2025.103080

Background
Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not recei... Read More about Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions (2025)
Journal Article
Kahan, B. C., Juszczak, E., Beller, E., Birchenall, M., Chan, A.-W., Hall, S., Little, P., Fletcher, J., Golub, R. M., Goulao, B., Hopewell, S., Islam, N., Zwarenstein, M., Elbourne, D., & Montgomery, A. (2025). Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions. BMJ, 388, Article e080785. https://doi.org/10.1136/bmj-2024-080785

This report presents the explanation and elaboration paper for the CONSORT (Consolidated Standards of Reporting Trials) 2010 and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 extensions for factorial trials. Factori... Read More about Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY) (2025)
Preprint / Working Paper
Horby, P. W., Emberson, J. R., Peto, L., Staplin, N., Campbell, M., Pessoa-Amorim, G., Stewart, R., Ghosh, D., Cooke, G., Blencowe, N., Moreno-Cuesta, J., Desai, P., Hine, P., Underwood, J., Easom, N., Majumdar, J., Bhagani, S., Baillie, J. K., Buch, M. H., Faust, S. N., …Group RECOVERY Collaborative. (2025). Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

Background Sotrovimab is a neutralising monoclonal antibody that has been proposed as a treatment for patients admitted to hospital with COVID-19.

Methods In this randomised, controlled, open-label platform trial, several possible treatments were... Read More about Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY).

Evaluating the Cost‐Effectiveness of Antenatal Screening for Major Structural Anomalies During the First Trimester of Pregnancy: A Decision Model (2025)
Journal Article
Campbell, H. E., Karim, J. N., Papageorghiou, A. T., Wilson, E. C., Rivero-Arias, O., & ACCEPTS Study. (2025). Evaluating the Cost‐Effectiveness of Antenatal Screening for Major Structural Anomalies During the First Trimester of Pregnancy: A Decision Model. BJOG: An International Journal of Obstetrics and Gynaecology, 132(5), 638-647. https://doi.org/10.1111/1471-0528.18053

Objective: To assess the cost-effectiveness of modifying current antenatal screening by adding first trimester structural anomaly screening to standard of care second trimester anomaly screening.

Design: Health economic decision model. Setting: N... Read More about Evaluating the Cost‐Effectiveness of Antenatal Screening for Major Structural Anomalies During the First Trimester of Pregnancy: A Decision Model.